This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalent's Stock Gains on Q4 Earnings Beat, Gross Margin Up
by Zacks Equity Research
CTLT's solid segmental results led to an encouraging fiscal fourth-quarter performance, driving up share prices in after-hours trading.
iRhythm Technologies Launches Zio Monitoring Across Europe
by Zacks Equity Research
IRTC launches Zio monitor in Austria, Netherlands, Spain and Switzerland, which offers 14-day continuous ECG monitoring, enhancing arrhythmia diagnosis and patient care.
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
COO Stock Gains on Q3 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
Cooper Companies' solid segmental results led to an encouraging fiscal third-quarter performance, driving up share prices in after-hours trading.
Veeva Systems Q2 Earnings & Revenues Beat, Operating Margin Up Y/Y
by Zacks Equity Research
VEEV's fiscal second-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Maravai LifeSciences' Cygnus & TriLink Unveil AccuRes DNA Kits
by Zacks Equity Research
MRVI's Cygnus and TriLink introduce AccuRes kits, setting a new standard in host cell DNA quantification with unmatched sensitivity and specificity.
Phibro Q4 Earnings and Revenues Beat, Operating Margin Down
by Zacks Equity Research
PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.
Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care
by Zacks Equity Research
ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.
Stryker Rallies 19.8% Year to Date: What's Driving the Stock?
by Zacks Equity Research
SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
by Zacks Equity Research
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
Aveanna Stock Rallies 110% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
AVAH stock has the potential to continue its uptrend on the back of a better payer rate environment and its focus on high-paying customers.
Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024
by Zacks Equity Research
GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.
Quest Diagnostics Expands in North America With New Acquisition
by Zacks Equity Research
DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
by Zacks Equity Research
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes
by Zacks Equity Research
Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.
Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall
by Zacks Equity Research
Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.
Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
by Zacks Equity Research
The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System
by Zacks Equity Research
SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
by Zacks Equity Research
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
by Zacks Equity Research
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare
by Zacks Equity Research
Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.
Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks
by Zacks Equity Research
With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.
Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.